| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Division of Clinical Immunology,
Department of Surgery, and
Immunobiology Center, Mount Sinai School of Medicine, New York, NY 10029
We have previously reported that CTL were demonstrable early after inoculation of CMS5 fibrosarcoma cells, but that they disappeared within 3 wk. These mice were unable to reject a challenge with CMS5 tumor cells. Other studies demonstrated cell surface phenotype and signaling abnormalities of cells within the spleen. Since we assumed that such an environment would make it more difficult to elicit antitumor immune responses via immunotherapy, we asked whether resection of the tumor could reverse these abnormalities. Although early after tumor cell inoculation tumor resection leads to the development of immunity, the effect at late time points has not been studied critically. To test this, mice were inoculated s.c. with CMS5 cells and after 28 days the tumors were resected. We observed a gradual normalization of the cellular phenotype of the spleen. In particular, there was a decrease in the number of Mac1+/Gr1high cells and an increase in the number of CD3+ cells in the spleen within 24–48 h of tumor resection. By day 10, these values were normal. Levels of p56lck increased as well. The functional implications of these changes were illustrated by the reduced growth rate or the complete rejection of a challenge of tumor cells in the resected mice. Both CD4+ and CD8+ cells were involved in the restoration of tumor immunity. Our results suggested that tumor resection not only led to the reversal of immune suppression, but also unmasked a population of primed T cells able to mediate protective immunity.
This article has been cited by other articles:
|
|
 |
|
  K. A. Pilones, N. Kawashima, A. M. Yang, J. S. Babb, S. C. Formenti, and S. Demaria Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade Clin. Cancer Res., January 15, 2009; 15(2): 597 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Clark, S. R. Hingorani, R. Mick, C. Combs, D. A. Tuveson, and R. H. Vonderheide Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion Cancer Res., October 1, 2007; 67(19): 9518 - 9527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhang, A. L. Cote, V. C. de Vries, E. J. Usherwood, and M. J. Turk Induction of Postsurgical Tumor Immunity and T-Cell Memory by a Poorly Immunogenic Tumor Cancer Res., July 1, 2007; 67(13): 6468 - 6476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Popovic, H. J. Zeh III, and J. B. Ochoa Arginine and Immunity J. Nutr., June 1, 2007; 137(6): 1681S - 1686S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Suzuki, S. Kim, H.-K. Cheung, M. J. Corbley, X. Zhang, L. Sun, F. Shan, J. Singh, W.-C. Lee, S. M. Albelda, et al. A Novel Small-Molecule Inhibitor of Transforming Growth Factor {beta} Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection Cancer Res., March 1, 2007; 67(5): 2351 - 2359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Shakhar, N. Abudarham, R. Melamed, Y. Schwartz, E. Rosenne, and S. Ben-Eliyahu Amelioration of Operation-Induced Suppression of Marginating Pulmonary NK Activity using Poly IC: A Potential Approach to Reduce Postoperative Metastasis Ann. Surg. Oncol., February 1, 2007; 14(2): 841 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms. Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Song, Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1{beta}-Secreting Cells J. Immunol., December 15, 2005; 175(12): 8200 - 8208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity Clin. Cancer Res., September 15, 2005; 11(18): 6713 - 6721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Broomfield, A. Currie, R. G. van der Most, M. Brown, I. van Bruggen, B. W.S. Robinson, and R. A. Lake Partial, but not Complete, Tumor-Debulking Surgery Promotes Protective Antitumor Memory when Combined with Chemotherapy and Adjuvant Immunotherapy Cancer Res., September 1, 2005; 65(17): 7580 - 7584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Danna, P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease Cancer Res., March 15, 2004; 64(6): 2205 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kusmartsev, Y. Nefedova, D. Yoder, and D. I. Gabrilovich Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species J. Immunol., January 15, 2004; 172(2): 989 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Kruklitis, S. Singhal, P. Delong, V. Kapoor, D. H. Sterman, L. R. Kaiser, and S. M. Albelda Immuno-gene therapy with interferon-{beta} before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 123 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Terabe, S. Matsui, J.-M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. Transforming Growth Factor-{beta} Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte-mediated Tumor Immunosurveillance: Abrogation Prevents Tumor Recurrence J. Exp. Med., December 1, 2003; 198(11): 1741 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Melani, C. Chiodoni, G. Forni, and M. P. Colombo Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity Blood, September 15, 2003; 102(6): 2138 - 2145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kusmartsev and D. I. Gabrilovich Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species J. Leukoc. Biol., August 1, 2003; 74(2): 186 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, J. A. Van Ginderachter, L. Brys, P. De Baetselier, G. Raes, and A. B. Geldhof Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells J. Immunol., May 15, 2003; 170(10): 5064 - 5074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bronte, P. Serafini, C. De Santo, I. Marigo, V. Tosello, A. Mazzoni, D. M. Segal, C. Staib, M. Lowel, G. Sutter, et al. IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice J. Immunol., January 1, 2003; 170(1): 270 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Acres, P. Beverley, and S. Scholl Tumor Immunology and the Battle of Waterloo Mol. Cancer Ther., June 1, 2002; 1(8): 651 - 655. [Full Text] [PDF]
|
|
|
|
|
|
A. Mazzoni, V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello, and D. M. Segal Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism J. Immunol., January 15, 2002; 168(2): 689 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. I. Terrazas, K. L. Walsh, D. Piskorska, E. McGuire, and D. A. Harn Jr. The Schistosome Oligosaccharide Lacto-N-neotetraose Expands Gr1+ Cells That Secrete Anti-inflammatory Cytokines and Inhibit Proliferation of Naive CD4+ Cells: A Potential Mechanism for Immune Polarization in Helminth Infections J. Immunol., November 1, 2001; 167(9): 5294 - 5303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Atochina, T. Daly-Engel, D. Piskorska, E. McGuire, and D. A. Harn A Schistosome-Expressed Immunomodulatory Glycoconjugate Expands Peritoneal Gr1+ Macrophages That Suppress Naive CD4+ T Cell Proliferation Via an IFN-{gamma} and Nitric Oxide-Dependent Mechanism J. Immunol., October 15, 2001; 167(8): 4293 - 4302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Apolloni, V. Bronte, A. Mazzoni, P. Serafini, A. Cabrelle, D. M. Segal, H. A. Young, and P. Zanovello Immortalized Myeloid Suppressor Cells Trigger Apoptosis in Antigen-Activated T Lymphocytes J. Immunol., December 15, 2000; 165(12): 6723 - 6730. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
